CD276 and ependymoma: Several Phase I studies have tested CAR-T cells directed against GD2, HER2, and B7H3 antigens in diffuse midline gliomas (DMG) and other recurrent/refractory pediatric brain tumors, including ependymoma and medulloblastoma [216,251].